Antifungal preparation

FIELD: medicine, dermatology, pharmacy.

SUBSTANCE: invention relates to an antifungal preparation for external applying. The preparation comprises 2-chloro-4-nitrophenol, polyethylene glycol (PEG-400) and 50% ethyl alcohol. The preparation is used for treatment of epidermophytosis, trichophytosis, fungal eczema, cutaneous candidiasis and other diseases. Invention provides preparing the more effective antifungal preparation based on the domestic raw.

EFFECT: enhanced effectiveness of preparation, valuable medicinal properties.

2 ex

 

The invention relates to pharmaceutical industry and can be used in the production of pharmaceuticals, directly relates to antifungal drug for topical use in the treatment of Epidermophyton, trichophytia fungal eczema, candidiasis of the skin and other

Known drug “Nitrofungin”, used for the treatment of these diseases, firms SPO FA (Czech Republic). The product is a solution containing 2-chloro-4-NITROPHENOL -1 g triethylene glycol and 10 grams of alcohol 50% to 100 ml.

The active ingredient of the nitrofungin is 2-chloro-4-NITROPHENOL, providing antifungal activity (Medmaravis “Drugs” 1996, so 2, str).

This drug is taken as a prototype. However, the known drug has a high degree of resorption.

The technical result of the invention is to provide a more efficient product.

This result is achieved due to the fact that it is proposed to introduce into the composition of the medication polyethylene glycol (PEG-400)manufactured by the domestic industry. PEG-400 pharmacologically indifferent with long-term use, not moderates the skin, easily releases the drug substance, reduces exudation, edema, has a drying effect, etc. (Metalysis, Aquademie, Ugoma. Synthetic polymers in the domestic pharmaceutical PRA the tick. 1975, p.50-55).

The use of the proposed drug allows to obtain a technical result, namely, that by reducing the degree of resorption, renewal substance and drying RAS increases therapeutic effect of the drug, i.e. get more effective antifungal drug.

The invention consists in the following.

Antifungal drug containing the substance is 2-chloro-4-NITROPHENOL and alcohol, and as a component of expanding therapeutic effects of drugs and to prevent crystallization of the substance in the composition, the polyethylene glycol (PEG-400)manufactured by the domestic industry, in the following ratio of components, wt.%:

2-chloro-4-NITROPHENOL 1,0

PEG-400 10,0

Alcohol 50% to 100.0

Inventive step of the proposed drug is determined by the combined use of PEG-400 with 2-chloro-4-NITROPHENOL leads to more rapid healing of the affected areas of the skin diseases of fungal origin.

The solution is prepared as follows.

Example 1

First, prepare an alcoholic solution of 2-chloro-4-NITROPHENOL, 1 g of a substance dissolved in 91 ml of 50% alcohol.

Then to the resulting solution was added 10 g (9 ml) (PEG-400) polyethylene glycol and stirred for 0.5 hour until complete dissolution.

Ready is the first product is a solution of lemon-yellow color with a smell of alcohol.

PEG-400 - pharmacologically, indiferente, easier and better pays incorporated activetestsuite substances, resulting in improved therapeutic properties of the drug. In addition, dosage form containing PEG-400, prevents crystallization of the substance by evaporation of the alcohol and promotes rapid healing of wounds.

The drug was administered as follows.

Example 2

At the Department of dermatology of the Krasnoyarsk State medical Institute has conducted a comparative study of the Czech anti-drug “Nitrofungin and offer domestic product.

The proposed drug used in the treatment of patients with erythematous-squamous, disgidroticescoy, and intertriginoznoy this form may giperkineticeski forms of athlete's foot.

I-I group of patients (9 persons) received the Czech antifungal drug Nitrofungin” in parallel with the proposed drug (on one foot). Subsidence of the acute clinical symptoms (edema, erythema, moist) in patients receiving the proposed drug, was observed at 1-3 days after the start of treatment, while patients receiving “Nitrofungin”, positive dynamics was observed only within 3-5 days from the start of antifungal therapy.

The number of bed days spent in hospital, at the Aulnay-athlete's foot, receiving the proposed drug has an average of 12.6 bed days in patients with mycosis stop receiving “Nitrofungin”, 15,4 bed-day.

Comparative study of 2 drugs showed higher efficacy of the proposed drug, which was reflected in the rapid regression of the pathological elements, improving samochustvie patients and reducing the time of stay of patients in hospital.

II-I group of patients 30 people, which has been clinically diagnosed with athlete's foot. The control group consisted of 5 people (student volunteers)who had no clinical symptoms of athlete's foot. Age of patients ranged from 20 to 60 years. It was a group of 11 women and 19 men.

Within 20 days the drug was applied twice daily to areas of mycotic lesions of patients with various forms of athlete's foot.

As a result of this significant reduction soak in patients disgestrotical form of athlete's foot, followed by rapid drying of mycotic lesions lesions and epitelizaciei erosion, reduction and disappearance of itching.

In patients with erythematous-squamous and intertriginoznoy forms of athlete's foot there was a significant regression of erythema, Express epithelialization.

In the future, all patients received antifungal maintenance therapy, including application against the fungal ointments in combination with sanitation and hygiene activities (processing shoes and so on).

Recurrence of athlete's foot after applying the proposed drug during the follow-up period for patients (3-5 months) were observed. In addition, allergic reactions to the place of use of the drug in the patients and the volunteers were noted.

When applying the proposed drug revealed a higher efficiency of the regression of the pathological elements, improving the health of patients, it was also noted strong positive dynamics of the regression of the pathological elements, which indicates a good therapeutic properties of the drug.

The invention makes it possible to organize a cost-effective production of highly effective antifungal drug on the basis of domestic raw materials.

The drug may find application in the treatment of skin diseases.

Antifungal drug containing the substance 2-chloro-4-NITROPHENOL, ethyl alcohol 50%, characterized in that the composition additionally introduced polyethylene glycol (PEG-400) in the following ratio, wt.%:

2-Chloro-4-NITROPHENOL 1,0

Polyethylene glycol (PEG-400) 10,0

Ethyl alcohol 50% To 100.0



 

Same patents:

FIELD: medicine, cosmetics.

SUBSTANCE: the present innovation deals with, a) at least, one fungicide substance and b) at least, one water-soluble film-forming substance, where b)-component is chitosan derivative chosen out of hydroxyalkyl chitosans and carboxyalkyl chitosans; nail vanish that includes the above-mentioned composition, and nail vanish that includes, at least, one water-soluble film-forming substance chosen out of hydroxyalkyl chitosans and carboxyalkyl chitosans. The suggested nail vanish is of high fungicide action and is free of multiple dermatological and esthetic disadvantages.

EFFECT: higher efficiency of application.

23 cl, 10 ex, 1 tbl

The invention relates to a pharmacy, namely the creation of herbal medicines, exhibiting antifungal activity

The invention relates to chemical-pharmaceutical industry, in particular to the creation and production of tools for the treatment of skin diseases

The drug cundiff" // 2237487
The invention relates to the pharmaceutical industry, and is intended for the prevention and treatment of viral, bacterial and fungal infections

The invention relates to medicine, specifically to antifungal medicinal preparation containing as active ingredient a therapeutically effective amount of clotrimazole and targeted supplements, which are used lactose, starch, MCC, citric acid, salt of stearic acid

Antimycotic agent // 2233167
The invention relates to medicine, namely to Microbiology, and can be used as antifungal agents

The invention relates to a new compound of chemical formula I,

where R= H, -COCH3or their salts; the way they are received by cultivation of the strain SANK 13899 (FERM BP-6851) a microorganism of the genus Phoma; strain SANK 13899 (FERM BP-6851) a microorganism of the genus Phoma; therapeutic or preventive agent against fungal infections; method of treating or preventing fungal infectious diseases

The invention relates to medicine, specifically to methods of producing aqueous-alcoholic compositions on the basis of walnuts milky-wax ripeness and honey, with the addition of pollen and glycine, and can be used in the prevention of diseases associated with metabolic disorders, to enhance immunity and reduce stress, eliminate iodine deficiency, as antiviral, antihelminthic and antifungal agent

The invention relates to the field of medicine and relates to a pharmaceutical for the treatment of skin diseases

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with medicinal preparations designed as solution and indicated for therapeutic needs. Eye drops contain ciprofloxacin hydrochloride monohydrate being equivalent to 0.3% free foundation, a buffer system that keeps pH within 3.5-5.5 interval, as a conserving agent - benzalconium chloride and a s a stabilizer - the salt of disodium ethylenediamine tetraacetic acid, moreover, their range of osmolality values correspond to 150-450 mM/kg H2O. Eye drops should be obtained by preparing buffer system in which mannitol should be dissolved followed by the salt of disodium ethylenediamine tetraacetic acid, benzalconium chloride, ciprofloxacin hydrochloride. Then one should perform the control for the quality of obtained solution to be then filtered by applying sterilizing elements and packed. This innovation provides treatment of eyes at creating the pressure in an eye and at certain desired osmolality.

EFFECT: higher efficiency of therapy.

4 cl, 1 ex

Acyzol-based agent // 2247558

FIELD: pharmaceutical industry.

SUBSTANCE: invention provides novel nontoxic and highly bioavailable acyzol-based agent characterized by high activity in treatment of skin diseases, in restoration of structural skin processes, suppression of nevus pigmentosis, and flattening of folds.

EFFECT: increased assortment of skin-healing drugs.

7 cl, 4 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with mixing water for injections, conservation agent, metronidasol till complete dissolving at 50-60 C, adding a buffer (NaOH solution) pH 4.5-6.5 at pre-estimated quantity of water, then one should sterilize the obtained medicinal form due to membranous filtration followed by sterile packaging. As a conservation agent one should apply sodium chloride at the quantity of 1.5-2.0 against metronidasol weight, then metronidasol solution should be supplemented with a half-volume of sodium chloride solution, after complete dissolving the obtained solution should be supplemented with the rest quantity of sodium chloride solution. As for membranous filtration it should be carried out by applying a capsule out of polypropylene with hydrophilic membrane of 1.2 mcm. The method provides no crystallization of an active substance during prolonged period of time.

EFFECT: higher therapeutic efficiency.

1 ex, 1 tbl

FIELD: pharmacology, fluorinated quinolone-based drug, in particular ofloxacine for injections.

SUBSTANCE: claimed composition contains therapeutically acceptable amount of ofloxacine and trilon-B, sodium chloride, water for injections as additives.

EFFECT: high therapeutic effectiveness; non-crystallized active agent for a long-time storage.

1 ex

The invention relates to the field of pharmaceutical industry and relates to aqueous solution for parenteral nutrition mammals

The invention relates to new pharmaceutical compositions that contain the basis or agonist of the basis for the treatment of diabetes, slowing of gastric emptying or reduce food intake, and their dosage forms and methods for their introduction

The invention relates to the field of pharmaceutical industry and relates to a treatment for scabies

The invention relates to pharmaceutical industry and relates to the preparation of dalargin for injection, used as a medicine in the acute gastric ulcer and duodenal ulcer, acute pancreatitis and pancreonecrosis

The invention relates to medicine, in particular to ophthalmology

FIELD: medicine, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to compositions used for treatment and/or prophylaxis of chlamydium infections caused by C. pheumoniae. Pharmaceutical composition used for treatment and/or prophylaxis of chlamydium infection caused by C. pneumoniae comprises the taken phenolic compound, or extract, or fraction, or incomplete fraction comprising the taken phenolic compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction obtained from plants and comprising indicated compound or corresponding synthetic compound on C. pneumoniae represents the definite percent of inhibition for formation of inclusions. The composition useful for health eliciting an anti-chlamydium effect with respect to C. pneumoniae comprises the taken phenolic compound or extract, or fraction, or incomplete fraction containing indicated compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent for inhibition in formation of inclusions. Also, invention relates to applying the composition useful for health in preparing foodstuffs or as supplements for nutrition for every day. Also, invention relates to applying phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound or mixture of indicated compounds obtained from plants in manufacturing a medicinal agent used for treatment and/or prophylaxis of chlamydium infections caused by C. pneumoniae. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent in inhibition in formation of inclusions. Compositions promote to effective prophylaxis and treatment of chlamydium infections caused by C. pneumoniae.

EFFECT: valuable medicinal properties of compounds.

21 cl, 1 dwg, 1 tbl, 6 ex

Up!